Immune‐related mechanisms participating in resistance and susceptibility to glutamate toxicity
暂无分享,去创建一个
Hadas Schori | Michal Schwartz | Adi Kimchi | Eti Yoles | M. Schwartz | A. Kimchi | E. Yoles | L. Wheeler | T. Raveh | H. Schori | Tal Raveh | Larry A Wheeler
[1] B. Meldrum,et al. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. , 2000, The Journal of nutrition.
[2] C. L. Schlamp,et al. Experimental induction of retinal ganglion cell death in adult mice. , 1999, Investigative ophthalmology & visual science.
[3] E. Hauben,et al. Neuronal Survival after CNS Insult Is Determined by a Genetically Encoded Autoimmune Response , 2001, The Journal of Neuroscience.
[4] R. Hogan,et al. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin , 2000, Epilepsy Research.
[5] E. Yoles,et al. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. , 1997, Journal of neurotrauma.
[6] E. Dreyer. A proposed role for excitotoxicity in glaucoma. , 1998, Journal of glaucoma.
[7] L A Wheeler,et al. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. , 1999, Investigative ophthalmology & visual science.
[8] Xiao-jun Xu,et al. Possible impact of genetic differences on the development of neuropathic pain-like behaviors after unilateral sciatic nerve ischemic injury in rats , 2001, Pain.
[9] P. Lipton,et al. Ischemic cell death in brain neurons. , 1999, Physiological reviews.
[10] K. Kieburtz. Antiglutamate therapies in Huntington's disease. , 1999, Journal of neural transmission. Supplementum.
[11] H. Abe,et al. Protective effect of microglial conditioning medium on neuronal damage induced by glutamate , 2000, Neuroscience Letters.
[12] R. Wen,et al. α2-Adrenergic Agonists Induce Basic Fibroblast Growth Factor Expression in Photoreceptors In Vivo and Ameliorate Light Damage , 1996, The Journal of Neuroscience.
[13] S. Nakanishi. Molecular diversity of glutamate receptors and implications for brain function. , 1992, Science.
[14] K. Do,et al. Glial‐derived arginine, the nitric oxide precursor, protects neurons from NMDA‐induced excitotoxicity , 2001, The European journal of neuroscience.
[15] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[16] H. Nakanishi,et al. Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide , 1999, Neuroscience.
[17] M. Schwartz,et al. Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. , 2001, Trends in molecular medicine.
[18] S. Kohsaka,et al. Ability of rat microglia to uptake extracellular glutamate , 2001, Neuroscience Letters.
[19] S. Tsirka,et al. Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus , 1998, Current Biology.
[20] A. Laties,et al. Alpha2-adrenergic agonists selectively activate extracellular signal-regulated kinases in Müller cells in vivo. , 1998, Investigative ophthalmology & visual science.
[21] A. Kimchi,et al. DAP-kinase: from functional gene cloning to establishment of its role in apoptosis and cancer , 2001, Cell Death and Differentiation.
[22] H. Nakanishi,et al. AMPA–Kainate Subtypes of Glutamate Receptor in Rat Cerebral Microglia , 2000, The Journal of Neuroscience.
[23] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[24] D. Pitt,et al. Glutamate excitotoxicity--a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis? , 2000, Journal of neural transmission. Supplementum.
[25] A. Kimchi,et al. Death-associated Protein (DAP) Kinase Plays a Central Role in Ceramide-induced Apoptosis in Cultured Hippocampal Neurons* , 2002, The Journal of Biological Chemistry.
[26] I. Screpanti,et al. Expression of metabotropic glutamate receptors in murine thymocytes and thymic stromal cells , 2000, Journal of Neuroimmunology.
[27] T. Rauen,et al. Glia-neuron interaction by high-affinity glutamate transporters in neurotransmission. , 1999, Advances in experimental medicine and biology.
[28] Charles Tator,et al. Effects of MK801 on evoked potentials, spinal cord blood flow and cord edema in acute spinal cord injury in rats , 1999, Spinal Cord.
[29] N. Fountain. Status Epilepticus: Risk Factors and Complications , 2000, Epilepsia.
[30] Gustavo Droguett,et al. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation , 2000, Nature Cell Biology.
[31] M. Hirayama,et al. MK-801 is cytotoxic to microglia in vitro and its cytotoxicity is attenuated by glutamate, other excitotoxic agents and atropine Possible presence of glutamate receptor and muscarinic receptor on microglia , 2001, Brain Research.
[32] T. Olsson,et al. Neurodegeneration and glial activation patterns after mechanical nerve injury are differentially regulated by non‐MHC genes in congenic inbred rat strains , 2001, The Journal of comparative neurology.
[33] J. Kukkonen,et al. Coupling of Astroglial α2‐Adrenoreceptors to Second Messenger Pathways , 1996 .
[34] C. Vorwerk,et al. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. , 1999, Survey of ophthalmology.
[35] E. Hauben,et al. Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7--2 (CD86) and prevention of cyst formation. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] L A Wheeler,et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[37] D. Dormont,et al. Na+-Dependent High-Affinity Glutamate Transport in Macrophages1 , 2000, The Journal of Immunology.
[38] Olney Jw. NEUROTOXICITY OF NMDA RECEPTOR ANTAGONISTS : AN OVERVIEW , 1994 .
[39] D. McCarthy,et al. The Low‐Affinity, Use‐Dependent NMDA Receptor Antagonist AR‐R 15896AR: An Update of Progress in Stroke , 1999, Annals of the New York Academy of Sciences.
[40] J. González-Mora,et al. Opposite effects of low and high doses of arginine on glutamate-induced nitric oxide formation in rat substantia nigra , 2001, Neuroscience Letters.
[41] E. Agranov,et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. , 2001, The Journal of clinical investigation.
[42] K. Lees,et al. Clinical experience with excitatory amino acid antagonist drugs. , 1995, Stroke.
[43] Hadas Schori,et al. T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system , 2001, Journal of Neuroimmunology.
[44] D. Zurakowski,et al. Ganglion cell loss after optic nerve crush mediated through AMPA-kainate and NMDA receptors. , 2000, Investigative ophthalmology & visual science.
[45] R. Dempsey,et al. Attenuation of brain edema, blood-brain barrier breakdown, and injury volume by ifenprodil, a polyamine-site N-methyl-D-aspartate receptor antagonist, after experimental traumatic brain injury in rats. , 2000, Neurosurgery.
[46] H. Neumann,et al. Neuronal Control of MHC Class II Inducibility in Rat Astrocytes and Microglia , 1996, European Journal of Neuroscience.
[47] R. Bullock,et al. Glutamate and its receptors in the pathophysiology of brain and spinal cord injuries. , 1998, Progress in brain research.
[48] J. Olney. Neurotoxicity of NMDA receptor antagonists: an overview. , 1994, Psychopharmacology bulletin.
[49] C. Ikonomidou,et al. Neuronal death enhanced by N-methyl-D-aspartate antagonists. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[50] P. Panzarasa,et al. Astrocytes as active participants of glutamatergic function and regulators of its homeostasis. , 1999, Advances in experimental medicine and biology.
[51] M. Schwartz,et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[52] J. Dahl,et al. Effect of Oral Ketamine on Secondary Hyperalgesia, Thermal and Mechanical Pain Thresholds, and Sedation in Humans , 2000, Regional Anesthesia & Pain Medicine.
[53] F. Tortella,et al. Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: in vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies. , 2000, The Journal of pharmacology and experimental therapeutics.
[54] M. Inatani,et al. Neuroprotective effects of brain-derived neurotrophic factor in eyes with NMDA-induced neuronal death , 2000, Brain Research.
[55] T. Olsson,et al. Genetic Regulation of Nerve Avulsion‐Induced Spinal Cord Inflammation , 2000, Annals of the New York Academy of Sciences.
[56] A. Privat,et al. Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats , 2000, Brain Research.
[57] M. Moskowitz,et al. Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.
[58] A. Heslegrave,et al. Nitric oxide‐dependent damage to neuronal mitochondria involves the NMDA receptor , 2002, The European journal of neuroscience.
[59] J. Kukkonen,et al. Coupling of astroglial alpha 2-adrenoreceptors to second messenger pathways. , 1996, Journal of neurochemistry.